Ligand Pharmaceuticals Inc. (LGND) Stock Quote

Detailed Quote for Ligand Pharmaceuticals Inc. (LGND) 
$ 14.70   0.23 (+1.59%) Volume: 360.54 k 4:00 PM EST Feb 10, 2012
Today 5d 1m 3m 1y more
Last Price
14.70
Change $
0.23
Change %
1.59%
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
14.65
High
15.43
Low
14.195
Prev Close
14.47
Last Trade
2/10/12
Volume
360.54 k
52 Wk Hi
16.24
52 Wk Low
9.00
Market Cap
289.2 m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
19,673,693
EPS (TTM)
0.52
PE Ratio
28.30
Exchange
NSD
News and Media for Ligand Pharmaceuticals Inc.  (LGND) 
Sector News | Topic News
News for LGND
Thu, Feb 09, 2012
12:45 PM Ligand to Present at the BIO CEO and Investor Conference on February 13 - Business Wire
Tue, Feb 07, 2012
4:05 PM Ligand Reports Fourth Quarter and Full Year 2011 Financial Results - Business Wire
8:00 AM Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development - Business Wire
Wed, Feb 01, 2012
9:45 PM Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings - Business Wire
12:30 PM Ligand to Report Fourth Quarter Results on February 7 - Business Wire
Wed, Jan 04, 2012
5:30 PM Ligand to Present at the Biotech Showcase Conference on January 10th - Business Wire
Wed, Dec 21, 2011
8:00 AM Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly - Business Wire
Mon, Dec 12, 2011
4:30 PM Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology - Business Wire
Wed, Dec 07, 2011
5:35 PM Ligand to Present at the Oppenheimer Healthcare Conference on December 14 - Business Wire
Tue, Sep 27, 2011
9:11 AM Factors Moving Markets, Worldwide View - Equity Research on Ligand Pharmaceuticals Inc. and Eli Lilly & Co. - Marketwire
Tue, Dec 01, 2009
7:05 AM New recombinant XYNTHA(TM) now available for patients with hemophilia A - Canada Newswire
7:03 AM Le nouveau produit recombinant XYNTHA(MC) est maintenant offert aux patients atteints d'hémophilie A - Canada Newswire
Tue, Sep 22, 2009
12:26 PM New H1N1 Treatment Could See Fast Approval From FDA - Accesswire
Mon, Sep 21, 2009
5:17 AM Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases - Canada Newswire
Fri, Sep 18, 2009
3:06 PM CEO says CEL-SCI could suddenly become a very important company - Accesswire
Tue, Jun 16, 2009
10:20 AM ANAVEX appoints Dr. Herve de Kergrohen as CEO to lead company through clinical trials and future growth - Accesswire
More News for LGND >>

Tags for Ligand Pharmaceuticals Inc.

Research stocks or mutual funds related to Ligand Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to LGND. The keywords below have been associated to LGND by either user submission or electronic means.

biotechnology company aventis pharmaceuticals stock trading identity theft alert pharmaceuticals research direct marketing fare alerts marketing communications pharmaceutical market stock market shares pharmaceuticals companies generic pharmaceutical pharmaceuticals logistics pharmaceutical investment ligand pharmaceutical niche pharmaceutical 1st alert email stock alert weather alerts diabetes alert business strategies database marketing pharmaceutical research and development fx alert stock toolbar stock alert biotech and pharmaceutical dupont pharmaceuticals pharma marketing gsk traffic alerts stock quote osteoporosis treatment school alert pharmaceutical software pharma manufacturing pharmaceutical clinical research severe weather alerts stock alerts stock price list pharmaceuticals jobs pharma license rfp pharmaceuticals research consultants pfizer pharmaceutical company novartis pharmaceuticals stock market alerts kv pharmaceutical company mobile phone alert warrick pharmaceutical